Related Experiment Video
Updated: Aug 6, 2026
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
Prognostic value of TRIM24 expression in gastric cancer and various human solid tumours: a comprehensive
Ali Beheshti Namdar1, Pegah Bahrami2, Ladan Goshayeshi1
1Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Introduction:
Tripartite motif-containing 24 (TRIM24) protein has been reported to be dysregulated in various cancers.
Aim:
This study assessed the TRIM24 expression pattern in patients with gastric cancer (GC). Additionally, a comprehensive meta-analysis was performed to clarify the importance of TRIM24 expression in predicting the outcomes of various malignancies.
Material And Methods:
The expression levels of TRIM24 in 40 cancerous and adjacent normal tissues were determined by quantitative real-time PCR (qRT-PCR). Patients were further classified into two groups based on high and low TRIM24 levels. The relationship between TRIM24 expression, various clinical features, b-catenin, and overall survival (OS) was evaluated using appropriate statistical analyses. Additionally, a comprehensive meta-analysis was conducted to assess the prognostic value of TRIM24 levels in various malignancies. The pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence interval (CI) were calculated to estimate the possible associations.
Results:
TRIM24 expression was higher in GC tissues compared with their corresponding normal tissues (fold change = 2.69, p = 0.009). TRIM24 overexpression was associated with increased levels of b-catenin, and shorter OS in GC patients (HR = 3.94, 95% CI: 1.06-14.60, p = 0.041). A meta-analysis of 24 eligible publications with 3639 patients also revealed a significant association between TRIM24 expression and shorter OS (HR = 2.01, 95% CI: 1.49-2.69, p < 0.001). TRIM24 expression was also predictive of lymph node metastasis (LNM) (OR = 1.70, 95% CI: 1.04-2.78, p = 0.036) and tumour stage (OR = 2.46, 95% CI: 1.74-3.47, p < 0.001).
Conclusions:
TRIM24 overexpression is strongly associated with tumour staging, metastasis, and unfavourable survival outcomes, highlighting its potential utility as both a useful prognostic marker and a potential therapeutic target across various malignancies.
